Prevalence of disability improvement in relapsing–remitting multiple sclerosis patients treated with cladribine tablets-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prevalence of disability improvement in relapsing–remitting multiple sclerosis patients treated with cladribine tablets

Published:2022-03-15 Issue:7 Volume:29 Page:2144-2147
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Signori Alessio¹^ORCID,Ponzano Marta¹^ORCID,Alexandri Nektaria²^ORCID,Giovannoni Gavin³,Sormani Maria Pia¹⁴

Affiliation:

1. Department of Health Sciences (DISSAL) University of Genoa Genoa Italy

2. Merck KGaA Darmstadt Germany

3. Blizard Institute, Barts and The London School of Medicine and Dentistry Queen Mary University of London London UK

4. Ospedale Policlinico San Martino IRCCS Genoa Italy

Funder

Merck KGaA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.15316

Reference6 articles.

1. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

2. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

3. Prevalence of disability improvement as a potential outcome for multiple sclerosis trials

4. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

5. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy;Frontiers in Neurology;2024-04-04

2. Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study);Current Neuropharmacology;2024-01

3. Assessing the duration of EDSS improvement after a therapy start: A novel approach applied to the long-term extension of the PRISMS study;Multiple Sclerosis and Related Disorders;2023-11

4. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis;Advances in Therapy;2023-09-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3